ALKSAlkermes plc

Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry productsLYBALVI (olanzapine and samidorphan) and ARISTADA (aripiprazole lauroxil)and its ongoing involvement in sleep medicine. The data presented...

Alkermes shares climbed after phase 3 LUMRYZ data met key endpoints in idiopathic hypersomnia as analysts raised price targets.read more...

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ (sodium oxybate) extended-release oral suspension in adults with idiopathic...

Alkermes reports positive Q1 results, beating expectations. Raises EPS guidance and maintains sales guidance. Analysts raise price targets.read more...

ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.

Wells Fargo & Company boosted their price target on shares of Alkermes from $43.00 to $44.00 and gave the company an "overweight" rating in a report on Wednesday...

Needham & Company LLC increased their target price on Alkermes from $45.00 to $50.00 and gave the company a 'buy' rating in a research note on Wednesday...

Alkermes (NASDAQ:ALKS) Reaches New 52-Week High - Time to Buy...

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...